Literature DB >> 3118992

Response to the combined administration of interferons alpha and gamma after failure of single interferon therapy in chronic myelogenous leukaemia.

O Kloke1, R Becher, N Niederle.   

Abstract

A previously untreated patient with benign phase chronic myelogenous leukaemia (CML) was treated with recombinant Interferon alpha-2 b. Haematological remission was induced for a total of twelve months. Thereafter, the patient developed resistance to Interferon alpha manifested by an increase in leucocyte counts despite dose escalation (up to 7 x 10(6) IU/day s.c.). Subsequent treatment with recombinant Interferon gamma failed to control myeloid proliferation. However, combined administration of both Interferon alpha and Interferon gamma resulted in a renewed haematological remission which lasted six months.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3118992     DOI: 10.1007/bf00367463

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  16 in total

1.  Potentiation of interferon action by mixtures of recombinant DNA-derived human interferons.

Authors:  W R Fleischmann; C M Fleischmann; W Fiers
Journal:  Antiviral Res       Date:  1984-12       Impact factor: 5.970

2.  Evidence that types I and II interferons have different receptors.

Authors:  A A Branca; C Baglioni
Journal:  Nature       Date:  1981-12-24       Impact factor: 49.962

Review 3.  Interferons: biochemical, cell growth inhibitory, and immunological effects.

Authors:  E C Borden; L A Ball
Journal:  Prog Hematol       Date:  1981

4.  Down-regulation of the interferon receptor.

Authors:  A A Branca; C Baglioni
Journal:  J Biol Chem       Date:  1982-11-25       Impact factor: 5.157

5.  Human leukocyte interferon preparation blocks granulopoietic differentiation.

Authors:  D S Verma; G Spitzer; J U Gutterman; A R Zander; K B McCredie; K A Dicke
Journal:  Blood       Date:  1979-12       Impact factor: 22.113

6.  [alpha 2-interferon: preliminary treatment results in chronic myeloid leukemia].

Authors:  N Niederle; O Kloke; C Doberauer; R Becher; D W Beelen; C G Schmidt
Journal:  Dtsch Med Wochenschr       Date:  1986-05-16       Impact factor: 0.628

7.  Down-regulation of peripheral blood cell interferon receptors in chronic myelogenous leukemia patients undergoing human interferon (HuIFN alpha) therapy.

Authors:  B L Maxwell; M Talpaz; J U Gutterman
Journal:  Int J Cancer       Date:  1985-07-15       Impact factor: 7.396

8.  Relationship of the clinical response and binding of recombinant interferon alpha in patients with lymphoproliferative diseases.

Authors:  C R Faltynek; G L Princler; J L Rossio; F W Ruscetti; A E Maluish; P G Abrams; K A Foon
Journal:  Blood       Date:  1986-04       Impact factor: 22.113

9.  Chronic myelogenous leukaemia: haematological remissions with alpha interferon.

Authors:  M Talpaz; K McCredie; H Kantarjian; J Trujillo; M Keating; J Gutterman
Journal:  Br J Haematol       Date:  1986-09       Impact factor: 6.998

10.  The synergistic influence of human interferon-gamma and interferon-alpha on suppression of hematopoietic progenitor cells is additive with the enhanced sensitivity of these cells to inhibition by interferons at low oxygen tension in vitro.

Authors:  H E Broxmeyer; S Cooper; B Y Rubin; M W Taylor
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

View more
  2 in total

1.  Treatment of chronic myelogenous leukemia with interferons alpha and gamma.

Authors:  O Kloke; D May; U Wandl; R Becher; B Opalka; U Beer; N Niederle
Journal:  Blut       Date:  1990-07

2.  Treatment of Ph+ chronic myeloid leukemia by gamma interferon.

Authors:  D Russo; R Fanin; E Zuffa; C Gallizia; M Grazia Michieli; D Damiani; N Testoni; V Pecile; G Visani; R Colombini
Journal:  Blut       Date:  1989-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.